{"nctId":"NCT00092495","briefTitle":"Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)","startDateStruct":{"date":"2002-12"},"conditions":["Cervical Cancer","Genital Warts"],"count":3055,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Biological: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Biological: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine"]},{"label":"3","type":"EXPERIMENTAL","interventionNames":["Biological: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine"]},{"label":"4","type":"EXPERIMENTAL","interventionNames":["Biological: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine"]}],"interventions":[{"name":"V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine","otherNames":["V501","Gardasil"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy adolescents and pre-adolescents with no prior sexual history\n* Healthy women who have an intact uterus with lifetime history of 0-4 sexual partners\n\nExclusion Criteria:\n\n* Prior Human Papillomavirus (HPV) vaccination\n* Prior abnormal Paps\n* Prior history of genital warts","healthyVolunteers":true,"sex":"ALL","minimumAge":"10 Years","maximumAge":"23 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Who Seroconverted for HPV 6 by Week 4 Postdose 3","description":"Seroconversion is defined as going from seronegative to seropositive.\n\nSeropositivity is defined as an anti-HPV 6 titer ≥ 20 milliMerck units per milliliter (mMU/mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"423","spread":null},{"groupId":"OG001","value":"428","spread":null},{"groupId":"OG002","value":"320","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) for HPV 6 by Week 4 Postdose 3","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"987.3","spread":null},{"groupId":"OG001","value":"1116.1","spread":null},{"groupId":"OG002","value":"603.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Who Seroconverted for HPV 6 by Week 4 Postdose 3","description":"Seroconversion is defined as going from seronegative to seropositive.\n\nSeropositivity is defined as an anti-HPV 6 titer ≥ 20 milliMerck units per milliliter (mMU/mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"372","spread":null},{"groupId":"OG001","value":"391","spread":null},{"groupId":"OG002","value":"363","spread":null},{"groupId":"OG003","value":"743","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) for HPV 6 by Week 4 Postdose 3","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"584.2","spread":null},{"groupId":"OG001","value":"704.5","spread":null},{"groupId":"OG002","value":"707.5","spread":null},{"groupId":"OG003","value":"798.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Who Seroconverted for HPV 11 by Week 4 Postdose 3","description":"Seroconversion is defined as going from seronegative to seropositive.\n\nSeropositivity is defined as an anti-HPV 11 titer ≥ 16 milliMerck units per milliliter (mMU/mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"423","spread":null},{"groupId":"OG001","value":"428","spread":null},{"groupId":"OG002","value":"320","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) for HPV 11 by Week 4 Postdose 3","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1264.0","spread":null},{"groupId":"OG001","value":"1396.5","spread":null},{"groupId":"OG002","value":"739.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Who Seroconverted for HPV 11 by Week 4 Postdose 3","description":"Seroconversion is defined as going from seronegative to seropositive.\n\nSeropositivity is defined as an anti-HPV 11 titer ≥ 16 milliMerck units per milliliter (mMU/mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"373","spread":null},{"groupId":"OG001","value":"391","spread":null},{"groupId":"OG002","value":"364","spread":null},{"groupId":"OG003","value":"743","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) for HPV 11 by Week 4 Postdose 3","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"632.1","spread":null},{"groupId":"OG001","value":"804.7","spread":null},{"groupId":"OG002","value":"836.2","spread":null},{"groupId":"OG003","value":"1003.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Who Seroconverted for HPV 16 by Week 4 Postdose 3","description":"Seropositivity is defined as an anti-HPV 16 titer ≥ 20 milliMerck units per milliliter (mMU/mL). Seroconversion is defined as going from seronegative to seropositive.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"424","spread":null},{"groupId":"OG001","value":"427","spread":null},{"groupId":"OG002","value":"306","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) for HPV 16 by Week 4 Postdose 3","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4848.8","spread":null},{"groupId":"OG001","value":"5923.0","spread":null},{"groupId":"OG002","value":"2753.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Who Seroconverted for HPV 16 by Week 4 Postdose 3","description":"Seroconversion is defined as going from seronegative to seropositive.\n\nSeropositivity is defined as an anti-HPV 16 titer ≥ 20 milliMerck units per milliliter (mMU/mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"365","spread":null},{"groupId":"OG001","value":"375","spread":null},{"groupId":"OG002","value":"364","spread":null},{"groupId":"OG003","value":"730","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) for HPV 16 by Week 4 Postdose 3","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2401.1","spread":null},{"groupId":"OG001","value":"2963.3","spread":null},{"groupId":"OG002","value":"3105.3","spread":null},{"groupId":"OG003","value":"3824.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Who Seroconverted for HPV 18 by Week 4 Postdose 3","description":"Seroconversion is defined as going from seronegative to seropositive.\n\nSeropositivity is defined as an anti-HPV 18 titer ≥ 24 milliMerck units per milliliter (mMU/mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"426","spread":null},{"groupId":"OG001","value":"428","spread":null},{"groupId":"OG002","value":"337","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) for HPV 18 by Week 4 Postdose 3","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"953.6","spread":null},{"groupId":"OG001","value":"1232.9","spread":null},{"groupId":"OG002","value":"470.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Who Seroconverted for HPV 18 by Week 4 Postdose 3","description":"Seroconversion is defined as going from seronegative to seropositive.\n\nSeropositivity is defined as an anti-HPV 18 titer ≥ 24 milliMerck units per milliliter (mMU/mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"381","spread":null},{"groupId":"OG001","value":"403","spread":null},{"groupId":"OG002","value":"375","spread":null},{"groupId":"OG003","value":"763","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) for HPV 18 by Week 4 Postdose 3","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"544.0","spread":null},{"groupId":"OG001","value":"640.4","spread":null},{"groupId":"OG002","value":"647.5","spread":null},{"groupId":"OG003","value":"696.9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":496},"commonTop":["Injection site pain","Headache","Injection site swelling","Injection site erythema","Pyrexia"]}}}